Research Paper Volume 16, Issue 16 pp 11939—11954
Identification of immunity- and ferroptosis-related signature genes as potential design targets for mRNA vaccines in AML patients
Figure 2. Tumor mutational burden of patients in the TCGA-LAML cohort. (A–E) The multiple forms of genomic mutations in the AML patients. (A) Variant classification. (B) Variant type. (C) SNV class. (D) Variants per sample. (E) Variant classification summary. (F) Mutations in the 10 most common genes. (G) The landscape of the genomic alterations in the top 30 genes per patient.